LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

LLY

911.36

-1.01%↓

UNH

597.64

+0.96%↑

NVO

117.53

+0.34%↑

JNJ

160.64

-0.12%↓

ABBV

194.4

-0.21%↓

Kodu・Aktsiate loetelu・Becton Dickinson and Co

Becton Dickinson and Co

Suletud

Sektor Tervishoid

238.58 0.6

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

234.69

Max

238.91

Põhinäitajad
By Trading Economics
Sissetulek	-50M 487M
Müük	10M 5.1B
P/E Sektori keskmine	50.04 113.916
Aktsiakasum	3.5
Kasumimarginaal	9.625
EBITDA	-124M 1.2B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+18.83 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. nov 2024
Järgmine dividendimakse kuupäev	27. dets 2024
Järgmine aktsia dividendi kuupäev (ex-date)	5. dets 2024

Turustatistika
By TradingEconomics
Turukapital	529M 70B
Eelmine avamishind	237.98
Eelmine sulgemishind	238.58

Uudiste sentiment

By Acuity

41%

59%

145 / 366 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

236.95 / 238.695 Toetus ja vastupanu

Becton Dickinson and Co Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. aug 2024, 11:08 UTC

Tulu

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3. juuni 2024, 11:18 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

2. mai 2024, 11:07 UTC

Tulu

Becton Dickinson Shakes Up 2024 Outlook After Growing 2Q Sales, Earnings

1. aug 2024, 10:37 UTC

Tulu

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1. aug 2024, 10:35 UTC

Tulu

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1. aug 2024, 10:35 UTC

Tulu

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1. aug 2024, 10:30 UTC

Tulu

Becton Dickinson 3Q EPS $1.68 >BDX

1. aug 2024, 10:30 UTC

Tulu

Becton Dickinson 3Q Net $487M >BDX

1. aug 2024, 10:30 UTC

Tulu

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1. aug 2024, 10:30 UTC

Tulu

Becton Dickinson 3Q Rev $5B >BDX

4. juuni 2024, 17:26 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3. juuni 2024, 15:30 UTC

Kuumad aktsiad

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3. juuni 2024, 13:26 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3. juuni 2024, 12:25 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

3. juuni 2024, 11:03 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2B in Cash

3. juuni 2024, 10:40 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences To Sell Its Critical Care Product Group For $4.2 Billion To Becton Dickinson -- MarketWatch

3. juuni 2024, 10:32 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson: Acquired Business Has About 4,500 Employees >BDX EW

3. juuni 2024, 10:31 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson: Acquired Business Generated More Than $900 Million Revenue in 2023 >BDX

3. juuni 2024, 10:31 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson: Deal Expands Portfolio of Smart Connected Care Solutions >BDX EW

3. juuni 2024, 10:30 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Buy Edwards Lifesciences Critical Care Product Group for $4.2 Billion >BDX EW

3. juuni 2024, 10:30 UTC

Omandamised, ülevõtmised, äriostud

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Billion To Expand Smart Connected Care Solutions And Become An Advanced Monitoring Technology Leader >BDX EW

2. mai 2024, 10:35 UTC

Tulu

Becton Dickinson Had Seen FY24 Adjusted EPS $12.82-$13.06 >BDX

2. mai 2024, 10:34 UTC

Tulu

Becton Dickinson Raises FY24 View To Adj EPS $12.95-Adj EPS $13.15 >BDX

2. mai 2024, 10:34 UTC

Tulu

Becton Dickinson Still Sees FY24 Organic Revenue Growth of 5.5%-6.25% >BDX

2. mai 2024, 10:33 UTC

Tulu

Becton Dickinson Had Seen FY24 Revenue $20.2B-$20.4B >BDX

2. mai 2024, 10:33 UTC

Tulu

Becton Dickinson Cuts FY24 View To Rev $20.1B-$20.3B >BDX

2. mai 2024, 10:30 UTC

Tulu

Becton Dickinson 2Q Net $537M >BDX

2. mai 2024, 10:30 UTC

Tulu

Becton Dickinson 2Q Adj EPS $3.17 >BDX

2. mai 2024, 10:30 UTC

Tulu

Becton Dickinson 2Q EPS $1.85 >BDX

2. mai 2024, 10:30 UTC

Tulu

Becton Dickinson 2Q Rev $5B >BDX

Võrdlus sarnastega

Hinnamuutus

Becton Dickinson and Co Prognoos

Hinnasiht

By TipRanks

18.83% tõus

12 kuu keskmine prognoos

Keskmine 281.83 USD 18.83%

Kõrge 312 USD

Madal 260 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Becton Dickinson and Co 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Becton Dickinson and Co aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

236.95 / 238.695Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

145 / 366 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Becton Dickinson and Co

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through segments such as BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.